"Rivaroxaban" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.
| Descriptor ID |
D000069552
|
| MeSH Number(s) |
D02.886.778.727 D03.383.533.640.713 D03.383.903.727
|
| Concept/Terms |
Rivaroxaban- Rivaroxaban
- 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide
|
Below are MeSH descriptors whose meaning is more general than "Rivaroxaban".
Below are MeSH descriptors whose meaning is more specific than "Rivaroxaban".
This graph shows the total number of publications written about "Rivaroxaban" by people in this website by year, and whether "Rivaroxaban" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 4 | 4 |
| 2016 | 7 | 1 | 8 |
| 2017 | 4 | 0 | 4 |
| 2018 | 1 | 4 | 5 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 2 | 5 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rivaroxaban" by people in Profiles.
-
Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations. Pharmacotherapy. 2022 10; 42(10):768-779.
-
Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. J Am Heart Assoc. 2021 11 16; 10(22):e021765.
-
Bilateral adrenal haemorrhage secondary to rivaroxaban in a patient with antiphospholipid syndrome. BMJ Case Rep. 2020 Jul 01; 13(7).
-
Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. Am Heart J. 2019 10; 216:117-124.
-
Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019 Aug; 180:37-42.
-
Therapeutic Plasma Exchange for Urgent Rivaroxaban Reversal. Tex Heart Inst J. 2018 04; 45(2):96-98.
-
The evolving role of dabigatran etexilate in clinical practice. Expert Opin Pharmacother. 2015; 16(13):2053-72.
-
Cardiac Tamponade Associated with Rivaroxaban. Del Med J. 2015 Jul; 87(7):206-7.
-
Novel oral anticoagulants: a review of new agents. Postgrad Med. 2013 Jul; 125(4):103-14.